LillyDirect UK: How It Works, Medicines Covered, and Safety Guidance

LillyDirect is a direct-to-patient healthcare platform created by Eli Lilly and Company, the global pharmaceutical manufacturer best known in the UK for Mounjaro (tirzepatide). Originally launched in the United States in early 2024, LillyDirect expanded to the United Kingdom in June 2026. The two services share a name but operate very differently, reflecting the distinct regulatory frameworks governing medicines supply in each country. This article explains how LillyDirect works, which medicines it covers, what the UK service actually offers, and the safety and regulatory considerations every patient should understand before using it.

What Is LillyDirect and How Does It Work?

LillyDirect is Eli Lilly's direct-to-patient platform: in the UK it acts solely as a dispensing and delivery service, as manufacturers cannot lawfully sell prescription-only medicines directly to patients under UK law.

LillyDirect is a direct-to-patient healthcare platform created by Eli Lilly and Company, one of the world's largest pharmaceutical manufacturers. It was introduced in the United States in early 2024, and in June 2026 Eli Lilly launched a LillyDirect service in the United Kingdom as well. The two services share a name but work quite differently, because the rules on how medicines can be supplied differ between the two countries.

In the United States, LillyDirect connects patients with independent, licensed telehealth clinicians who assess them, issue a prescription where appropriate, and arrange for medicines to be dispensed and delivered to the patient's home. It also lets eligible US patients buy certain Lilly medicines on a self-pay basis. In the United Kingdom, a manufacturer is not permitted to sell prescription-only medicines directly to patients, so LillyDirect operates only as a dispensing and delivery service: a UK-regulated healthcare provider must first issue a private prescription, after which Lilly's UK dispensing partners fulfil and deliver it. Eli Lilly has been clear that it plays no part in the clinical decisions about a patient's care.

In neither country does LillyDirect itself employ the prescribing clinicians. These are independent, licensed healthcare professionals. Eli Lilly's role is that of the manufacturer and platform facilitator, not the prescriber.

The model reflects a broader move towards direct-to-patient pharmaceutical services, which aim to reduce barriers to access and to help ensure patients receive genuine, correctly stored products. It also raises important questions around clinical oversight, continuity of care, and regulatory standards, and the way those questions are answered varies significantly between countries, and particularly between the US and the UK.

Which Medications and Conditions Does LillyDirect Cover?

UK LillyDirect currently covers Mounjaro (tirzepatide), licensed for type 2 diabetes and chronic weight management; key side effects include nausea, vomiting, and gastrointestinal disturbance, particularly during dose escalation.

LillyDirect is most closely associated with medicines used in type 2 diabetes and weight management (obesity), two areas that have seen major pharmaceutical innovation in recent years. The medicines most often linked with the platform include:

• Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This is an important point of confusion for UK readers: in the UK, tirzepatide is sold under a single brand, Mounjaro, which holds MHRA authorisation for both type 2 diabetes and chronic weight management. In the US, the same molecule is marketed under two brand names, Mounjaro (for type 2 diabetes) and Zepbound (for weight management and obstructive sleep apnoea). Zepbound is a US-only brand and is not licensed or available in the UK.

• Dulaglutide (Trulicity), a GLP-1 receptor agonist licensed in the UK for type 2 diabetes. It is not licensed for weight management.

• Orforglipron (Foundayo), Eli Lilly's oral GLP-1 pill, offered through US LillyDirect since 2026. At the time of writing it is not yet available in the UK.

• Insulin products and other Lilly medicines.

These medicines work by mimicking or enhancing the action of naturally occurring gut hormones that regulate blood glucose and appetite. GLP-1 receptor agonists stimulate insulin secretion in a glucose-dependent manner, suppress glucagon release, slow gastric emptying, and promote satiety.^[7][8] Weight-management indications apply only to products specifically licensed for that purpose (in the UK, tirzepatide as Mounjaro, or semaglutide as Wegovy) and should not be assumed to apply to the entire drug class.

Adverse effects associated with these drug classes include nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation.^[3][4] Other important risks include:

• Gallbladder disease (including cholelithiasis and cholecystitis)

• Dehydration and acute kidney injury, particularly if vomiting or diarrhoea is prolonged

• Hypoglycaemia, especially when used alongside insulin or a sulfonylurea

• Diabetic retinopathy complications, which may occur with rapid improvement in glycaemic control^[6]

• Pancreatitis: patients should seek urgent medical attention if they develop severe or persistent abdominal pain

A point worth clarifying, because the guidance differs by country: in animal studies, thyroid C-cell tumours have been observed with GLP-1-based therapies, and the clinical relevance in humans remains uncertain. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 is listed as a contraindication in the US prescribing information for these medicines, but it is not listed as a contraindication in the UK and EU Summary of Product Characteristics for Mounjaro, where the only contraindication is hypersensitivity to the active substance or excipients. Patients with any thyroid concerns should nonetheless raise them with their prescriber.

These medicines are not recommended during pregnancy or breastfeeding, and women of childbearing potential should be counselled about effective contraception.^[12] Patients should always be assessed and counselled about these risks by a qualified healthcare professional before starting treatment, and any suspected side effects should be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or the Yellow Card app).

Safety, Regulation, and Patient Considerations

UK patients should verify their prescriber is GMC-registered, the service is CQC-regulated, and the pharmacy is GPhC-registered; fragmented care and incomplete medicines reviews are the principal safety risks of online prescribing models.

From a patient-safety perspective, any direct-to-patient model raises considerations that matter regardless of who runs it. Where prescriptions are issued by an online or telehealth clinician rather than a patient's established GP or specialist, there is a potential risk of fragmented care, particularly for patients with complex comorbidities or those already taking several medicines. Drug interactions, contraindications, and the need for appropriate baseline investigations may not always be fully evaluated in a brief online consultation.

In the United States, the platform operates within FDA regulations and state-level medical licensing laws. In the United Kingdom, the regulatory landscape is distinct and involves several bodies with different responsibilities:

• MHRA (Medicines and Healthcare products Regulatory Agency): licenses medicines and monitors their safety (pharmacovigilance), including the Yellow Card scheme

• GMC (General Medical Council): regulates doctors, including those providing remote or online prescribing

• CQC (Care Quality Commission): regulates and inspects providers of online and independent healthcare services in England^[13]

• GPhC (General Pharmaceutical Council): regulates pharmacists and registered pharmacies, including those dispensing at a distance

Whichever service you use, whether the new UK LillyDirect dispensing route or another regulated provider, the same safety principles apply:

• Verify that the prescribing clinician is registered with the GMC (check the GMC online register)

• Verify that the online pharmacy is registered with the GPhC (check the GPhC online register) and displays the registered-pharmacy logo

• Ensure the provider is regulated by the CQC if operating in England (or the equivalent national regulator elsewhere in the UK)

• Inform your GP of any new medicines started through online or private services

• Be cautious of any service that does not require a thorough medical history, relevant baseline checks (such as HbA1c, renal function, weight and BMI, and a review of your other medicines), or ongoing monitoring

• Seek urgent medical attention for severe or persistent upper abdominal pain (possible pancreatitis or gallbladder disease), persistent vomiting or signs of dehydration, or sudden changes in vision

• Report suspected side effects via the MHRA Yellow Card scheme

These principles align with GMC guidance on remote prescribing, CQC standards for online healthcare providers, and NICE guidance on medicines optimisation and person-centred care.

Is LillyDirect Available in the UK?

Yes — LillyDirect has been available in the UK since June 2026, operating as a dispensing and delivery service for Mounjaro on private prescription through partners Pharmacy2U and Onescript.

Yes. Since June 2026, LillyDirect is available in the United Kingdom, although it works very differently from the US service. When LillyDirect first launched in the US in 2024 it was not open to UK patients, and a great deal of older coverage online still describes it as US-only. That changed on around 25 June 2026, when Eli Lilly launched LillyDirect in the UK.

In the UK, LillyDirect is a dispensing and delivery service only. Because a pharmaceutical manufacturer cannot lawfully sell prescription-only medicines directly to patients here, LillyDirect does not prescribe, and it does not set a US-style self-pay price. Instead:

• A UK-regulated healthcare provider (an online clinic or prescriber) must first assess you and, where appropriate, issue a private prescription for Mounjaro.

• That prescription is then dispensed and delivered by one of Lilly's UK dispensing partners (at launch, Pharmacy2U and Onescript from Blueco Healthcare).

• At launch, the only medicine offered through UK LillyDirect is Mounjaro (tirzepatide) on private prescription. Eli Lilly has said it will keep reviewing which medicines to add.

Eli Lilly's stated aim is to help patients receive genuine, correctly stored Mounjaro and to reduce the risk of counterfeit or falsified product entering the supply chain, a growing problem as fake weight-loss pens are sold online.

Crucially, UK LillyDirect does not replace clinical care: it plays no part in deciding whether tirzepatide is right for you, and it is not connected to the NHS. UK patients can also continue to access tirzepatide through the NHS or through other regulated private providers:

• NHS, type 2 diabetes: Mounjaro is available on the NHS for eligible patients with type 2 diabetes, in line with NICE technology appraisal TA924.

• NHS, weight management: NICE has recommended tirzepatide for managing overweight and obesity (TA1026), with access delivered through specialist services and phased in over several years, so NHS weight-management availability is currently limited and prioritised by clinical need.

• Regulated private providers: a number of CQC-registered clinics and online services prescribe Mounjaro privately after a proper assessment.

For UK patients, the key points are simple. Mounjaro is the licensed UK brand of tirzepatide, for both type 2 diabetes and weight management. Zepbound is a US-only brand and should not be sought or imported into the UK. Whichever route you choose, make sure the prescriber is GMC-registered, the service is CQC-regulated (or the equivalent national regulator), and the dispensing pharmacy is GPhC-registered. Now that Mounjaro is widely available through regulated UK routes, there is no need to take on the safety and legal risks of importing tirzepatide from US-based services.

Frequently Asked Questions